KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Depreciation and Depletion (2016 - 2022)

TherapeuticsMD (TXMD) has disclosed Depreciation and Depletion for 13 consecutive years, with $100000.0 as the latest value for Q4 2022.

  • For the quarter ending Q4 2022, Depreciation and Depletion rose 150.0% year-over-year to $100000.0, compared with a TTM value of $100000.0 through Sep 2023, down 66.67%, and an annual FY2022 reading of $600000.0, up 50.0% over the prior year.
  • Depreciation and Depletion was $100000.0 for Q4 2022 at TherapeuticsMD, down from $200000.0 in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $200000.0 in Q2 2020 and bottomed at -$200000.0 in Q4 2021.
  • Average Depreciation and Depletion over 5 years is $118461.1, with a median of $138125.0 recorded in 2019.
  • The sharpest move saw Depreciation and Depletion skyrocketed 200.5% in 2020, then plummeted 200.0% in 2021.
  • Year by year, Depreciation and Depletion stood at $59989.0 in 2018, then soared by 193.8% to $176250.0 in 2019, then increased by 13.48% to $200000.0 in 2020, then tumbled by 200.0% to -$200000.0 in 2021, then surged by 150.0% to $100000.0 in 2022.
  • Business Quant data shows Depreciation and Depletion for TXMD at $100000.0 in Q4 2022, $200000.0 in Q3 2022, and $200000.0 in Q2 2022.